Thanks President and Administration for recognizing importance of generics
WASHINGTON (May 18, 2026) — The Association for Accessible Medicines commented on the announcement today that TrumpRx will now include generic medicines.
“AAM is thankful to the President and the Administration for recognizing the importance and value generic and biosimilar medicines provide to American patients and we look forward to continuing to work together to advancing cost-saving solutions,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generics and Biosimilars are the single greatest area of potential savings for patents in the health care ecosystem.”
President Trump and the White House launched TrumpRx in February as a website that lists negotiated discounted drug prices from brand manufacturers. TrumpRx now also lists generic drugs.
According to TrumpRx: The prices on generic drugs listed on TrumpRx are displayed using private pharmacy discount aggregators to provide consumers with transparency into the best cash price discounts available to them. These prices may differ from those available to insured patients through their insurance companies. Insured patients should always check the TrumpRx price against those offered through their insurance companies.
U.S. Generic & Biosimilar Medicines Savings Report
Media contact: media@accessiblemeds.org
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at www.biosimilarscouncil.org.
